Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden

References

• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16(1):223–7. doi:10.1146/annurev-pathol-042020-042741.
   PubMed Web of Science ®Google Scholar
• Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, Bai L, Bian Y. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975. doi:10.3389/fimmu.2023.1167975.
   PubMedGoogle Scholar
• Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S. et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217–1238. doi:10.1016/j.annonc.2022.10.001.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, Krug LM, Moslehi J, Pietanza MC, Riemer J. et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer. 2023;11(3):e006398. doi:10.1136/jitc-2022-006398.
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580. doi:10.1038/s41571-019-0218-0.
   PubMed Web of Science ®Google Scholar
• Liu LL, Skribek M, Harmenberg U, Gerling M. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature. J Immunother Cancer. 2023;11(3):e005841. doi:10.1136/jitc-2022-005841.
   PubMed Web of Science ®Google Scholar
• Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123–e127. doi:10.1016/j.bbmt.2018.12.756.
   PubMedGoogle Scholar
• Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Müller-Tidow C, Dreger P. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34–48. doi:10.1016/j.annonc.2020.10.478.
   PubMed Web of Science ®Google Scholar
• Yomota M, Mirokuji K, Sakaguchi M, Kitahara Y, Chin F, Setoguchi K, Hosomi Y. Cytokine release syndrome induced by immune-checkpoint inhibitor therapy for non-small-cell lung cancer. Intern Med. 2021;60(21):3459–3462. doi:10.2169/internalmedicine.5922-20.
   PubMed Web of Science ®Google Scholar
• Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst A-M, Chan YH, Aminkeng F, Bharwani LD, Huang Y, Mak A. et al. Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol. 2022;13:807050. doi:10.3389/fimmu.2022.807050.
   PubMedGoogle Scholar
• Ceschi A, Noseda R, Palin K, Verhamme K. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database. Front Pharmacol. 2020;11:557. doi:10.3389/fphar.2020.00557.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. doi:10.1186/s40425-018-0343-9.
   PubMed Web of Science ®Google Scholar
• Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731–738. doi:10.1038/s41591-018-0041-7.
   PubMed Web of Science ®Google Scholar
• Higuera Gómez O, Moreno Paul A, Ortega Granados AL, Ros Martinez S, Perez Parente D, Ruiz-Gracia P, Saenz Cuervo-Arango L, Vila L. “High tumor burden” in metastatic non-small cell lung cancer: defining the concept. Cancer Manag Res. 2021;13:4665–4670. doi:10.2147/CMAR.S302928.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M, Finley GG, Kaul MD, Yu W, Paranthaman N. et al. Association of immune-related adverse events with efficacy of atezolizumab in patients with non–small cell lung cancer. JAMA Oncol. 2023;9(4):527–535. doi:10.1001/jamaoncol.2022.7711.
   PubMed Web of Science ®Google Scholar
• Amoroso V, Gallo F, Alberti A, Paloschi D, Ferrari Bravo W, Esposito A, Cosentini D, Grisanti S, Pedersini R, Petrelli F. et al. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies. ESMO Open. 2023;8(2):100787. doi:10.1016/j.esmoop.2023.100787.
   PubMed Web of Science ®Google Scholar
• Lin L, Liu Y, Chen C, Wei A, Li W. Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis. Front Pharmacol. 2023;14:1190001. doi:10.3389/fphar.2023.1190001.
   PubMedGoogle Scholar
• Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, Si L, Tang B, Cui C, Yang X. et al. Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti–PD-1 monotherapy. Clin Cancer Res. 2021;27(21):5993–6000. doi:10.1158/1078-0432.CCR-21-1283.
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306. doi:10.1186/s40425-019-0805-8.
   PubMed Web of Science ®Google Scholar
• Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442–447. doi:10.1038/s41577-020-0348-8.
   PubMed Web of Science ®Google Scholar
• Kharroubi SA, Diab-El-Harake M. Sex-differences in COVID-19 diagnosis, risk factors and disease comorbidities: a large US-based cohort study. Front Public Health. 2022;10:1029190. doi:10.3389/fpubh.2022.1029190.
   PubMed Web of Science ®Google Scholar